Rifaximin‐α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization
Rifaximin-α significantly reduced the number of episodes of hepatic encephalopathy, the number of hospital admissions as well as the number of outpatient and emergency department visits, contributing to a reduction in healthcare utilization. There was no reduction in overall costs.
Authors
- Philip W. Friederich (ORCID: https://orcid.org/0009-0004-6085-3694)
- Lubbertus C. Baak (ORCID: https://orcid.org/0000-0002-6730-2367)
- Xander G. Vos
- Diederick J. van Doorn (ORCID: https://orcid.org/0000-0003-3299-0654)
- Robert Bart Takkenberg (ORCID: https://orcid.org/0000-0003-2179-1385)
- Bart J. Verwer
- Koos de Wit (ORCID: https://orcid.org/0000-0001-8472-8549)
- Joost P.H. Drenth (ORCID: https://orcid.org/0000-0001-8027-3073)
- Michael Klemt‐Kropp (ORCID: https://orcid.org/0000-0002-7283-371X)
- G.J. de Bruin
- Kirsi. M. A. van Eekhout
Institutions
- Noordwest Ziekenhuisgroep (NL)
- Spaarne Ziekenhuis (NL)
- OLVG (NL)
- Tergooi (NL)
- Amsterdam University Medical Centers (NL)
- Meander Medisch Centrum (NL)
- Spaarne Gasthuis (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- United European Gastroenterology Journal
- Published
- 2025-04-30
- DOI
- https://doi.org/10.1002/ueg2.12767
- Primary Topic
- Travel-related health issues
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Norgine